Patents by Inventor David Stephen HEWINGS

David Stephen HEWINGS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NEW EGFR INHIBITORS
    Publication number: 20220315591
    Abstract: The invention provides novel compounds as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: June 19, 2020
    Publication date: October 6, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Cosimo DOLENTE, Annick GOERGLER, David Stephen HEWINGS, Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Roger David NORCROSS, Christa Ulrike OBST-SANDER, Antonio RICCI, Daniel RUEHER, Sandra STEINER
  • METHYLQUINAZOLINONE DERIVATIVES
    Publication number: 20220298119
    Abstract: The invention provides a novel compound having the general formula (I) or a pharmaceutically acceptable salt thereof. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: June 8, 2022
    Publication date: September 22, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Cosimo DOLENTE, David Stephen HEWINGS, Daniel HUNZIKER, Daniela KRUMMENACHER, Piergiorgio Francesco Tommaso PETTAZZONI, Juergen WICHMANN
  • BRAF INHIBITORS AS PARADOX BREAKERS
    Publication number: 20220298145
    Abstract: The invention provides a novel compound having the general formula (I) wherein R1-R3 and X are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: June 8, 2022
    Publication date: September 22, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Cosimo DOLENTE, David Stephen HEWINGS, Daniel HUNZIKER, Daniela KRUMMENACHER, Piergiorgio Francesco Tommaso PETTAZZONI, Juergen WICHMANN